Genomic Vision strengthens team

Appoints chief finance officer and vice president of research and development

Genomic Vision, a biotechnology company dedicated to DNA analysis with an innovative molecular combing nanotechnology, has appointed Erwan Martin as chief financial officer and Emmanuel Conseiller as vice president of research and development.

Prior to joining Genomic Vision, Martin was cfo at Cytomics Pharmaceuticals (2003–2008), a biopharmaceutical company he co-founded with Dominique Thomas (Research Director at the CNRS Centre for Molecular Genetics, Gif-sur-Yvette) and for which he led the first rounds of financing. Prior to this he worked for 10 years as a consultant for Syndex, an auditing firm.

Conseiller joined Genomic Vision in 2009 after working for more than 17 years as a senior manager at sanofi-aventis (primarily within the oncology division). He is a pioneer in the application of functional genomics to drug discovery (from drug target screening to clinical trials) and has designed and led several projects for drug screening (small molecules and gene therapy) in the fields of tumour suppression, DNA replication and tumour metabolism. He holds a PhD from Pierre and Marie Curie University, Paris. In 1997, he won the Rhone-Poulenc Rorer Research Prize for his work on the development of chimeric tumour suppressors for gene therapy of cancer.

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Manufacturing

Thermo Fisher launches general purpose centrifuges with natural refrigerant cooling

New X and S Series models offer high performance with reduced environmental impact
Research & Development

€2.5m boost for SensABLATE to revolutionise real-time lung cancer treatment

The next-generation AI and photonics system is designed to provide instant intraoperative confirmation during lung cancer ablation and aims to improve precision, reduce repeat procedures and enhance patient outcomes
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Subscribe now